CINECA IRIS Institutional Research Information System

CREMOLINI, CHIARA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 14.191
EU - Europa 4.952
AS - Asia 2.619
AF - Africa 266
SA - Sud America 12
OC - Oceania 10
Continente sconosciuto - Info sul continente non disponibili 6
Totale 22.056
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 13.956
IT - Italia 2.033
SG - Singapore 964
CN - Cina 928
SE - Svezia 817
BG - Bulgaria 626
DE - Germania 426
VN - Vietnam 294
GB - Regno Unito 285
CA - Canada 233
TR - Turchia 186
FI - Finlandia 175
CI - Costa d'Avorio 151
HK - Hong Kong 115
UA - Ucraina 114
FR - Francia 107
AT - Austria 84
RU - Federazione Russa 80
IN - India 68
PL - Polonia 55
CH - Svizzera 49
SN - Senegal 48
NG - Nigeria 45
BE - Belgio 27
NL - Olanda 20
JP - Giappone 18
CZ - Repubblica Ceca 12
KR - Corea 11
BJ - Benin 10
ES - Italia 9
BR - Brasile 8
GR - Grecia 8
AU - Australia 7
ID - Indonesia 7
EU - Europa 6
IR - Iran 6
TW - Taiwan 6
IE - Irlanda 5
MY - Malesia 5
EG - Egitto 4
IL - Israele 4
LU - Lussemburgo 4
DK - Danimarca 3
NZ - Nuova Zelanda 3
RO - Romania 3
TN - Tunisia 3
AR - Argentina 2
CY - Cipro 2
KE - Kenya 2
LV - Lettonia 2
NO - Norvegia 2
SK - Slovacchia (Repubblica Slovacca) 2
AG - Antigua e Barbuda 1
CL - Cile 1
CO - Colombia 1
CR - Costa Rica 1
DZ - Algeria 1
EE - Estonia 1
KH - Cambogia 1
KZ - Kazakistan 1
NP - Nepal 1
PH - Filippine 1
PT - Portogallo 1
RE - Reunion 1
SI - Slovenia 1
SM - San Marino 1
TH - Thailandia 1
ZA - Sudafrica 1
Totale 22.056
Salva come PNG Salva come JPEG
Città #
Woodbridge 1.995
Fairfield 1.614
Ann Arbor 1.424
Houston 1.274
Chandler 1.087
Ashburn 765
Seattle 709
Sofia 625
Wilmington 590
Cambridge 586
Milan 538
New York 481
Singapore 405
Boardman 384
Princeton 295
Beijing 287
Lawrence 283
Medford 235
Ottawa 216
Florence 173
Pisa 159
Dearborn 152
Abidjan 151
Des Moines 145
Jacksonville 138
Nanjing 128
Serra 119
Hong Kong 102
Istanbul 101
Dong Ket 97
Rome 93
Vienna 84
San Diego 83
Izmir 80
London 78
Düsseldorf 77
Ogden 74
Bremen 60
Redwood City 59
Lancaster 55
Shanghai 54
Warsaw 54
Nanchang 50
Dakar 48
Bern 46
Genoa 46
Lagos 45
Seacroft 41
Boulder 38
Shenyang 38
Kunming 37
Fuzhou 34
Lappeenranta 34
Jüchen 31
Norwalk 31
Hebei 30
Los Angeles 30
Frankfurt am Main 27
Marseille 27
Turin 25
Brussels 24
Changsha 23
Hefei 23
Naples 22
Gargallo 21
Kent 21
Santa Clara 21
Munich 19
Phoenix 17
Tianjin 17
Washington 17
Dallas 16
Guangzhou 16
Jiaxing 16
Positano 15
Pune 15
Quanzhou 15
Verona 14
Falls Church 13
Padova 12
Hyderabad 11
Livorno 11
Cotonou 10
Hangzhou 10
Palermo 10
Auburn Hills 9
Bologna 9
Capannori 8
Chicago 8
Grafing 8
Jinan 8
San Francisco 8
Chengdu 7
Groningen 7
San Miniato Basso 7
Carrara 6
Catania 6
Council Bluffs 6
Detroit 6
Kilburn 6
Totale 17.285
Salva come PNG Salva come JPEG
Nome #
OUTCOME OF SECOND-LINE TREATMENT AFTER FIRST-LINE CHEMOTHERAPY WITH THE GONO FOLFOXIRI REGIMEN. 160
Homeobox B9 mediates resistance to anti-VEGF therapy in colorectal cancer patients 154
EGFR ligands as pharmacodynamic biomarkers in metastatic colorectal cancer patients treated with cetuximab and irinotecan 153
TRIBE-2: A phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group 144
Pten expression and Kras mutations as predictors of benefit from cetuximab plus irinotecan (CETIRI) in metastatic colorectal cancer (MCRC) patients (PTS) 141
KRAS and BRAF mutational analyses in a phase II trial of first-line FOLFOXIRI plus bevacizumab (BV) in metastatic colorectal cancer (mCRC) patients (pts) 141
Randomized trial of two induction chemotherapy regimens in metastatic colorectal cancer: an updated analysis 136
TAS-102 for the treatment of metastatic colorectal cancer 134
Exploratory analysis of circulating pro-and anti-angiogenic factors in metastatic colorectal cancer (MCRC) patients, treated with GONO-folfoxiri plus bevacizumab (BV) 132
KRAS codon 61, 146 and BRAF V600E mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer 129
null 129
Heterogeneity of Acquired Resistance to Anti-EGFR Monoclonal Antibodies in Patients with Metastatic Colorectal Cancer 129
Circulating amphiregulin (AR) plasma levels as surrogate pharmacodynamic markers of EGFR inhibition with cetuximab in metastatic colorectal cancer (MCRC) patients 128
Analysis of PTEN expression and KRAS mutations on primaries (PRIM) and metastases (METS) to predict benefit from cetuximab plus irinotecan (CETIRI) in metastatic colorectal cancer (MCRC) patients (PTS) 127
Exploratory analysis of circulating pro-and anti-angiogenic factors in metastatic colorectal cancer (MCRC) patients, treated with GONO-folfoxiri plus bevacizumab (BV) 127
null 127
BRAF V600E mutation and amphiregulin (AR) immunohistochemical expression in the prediction of benefit from cetuximab plus irinotecan in KRAS wild-type metastatic colorectal cancer (mCRC) patients 126
Circulating angiogenic factors as predictors of benefit from bevacizumab (bev) beyond progression in metastatic colorectal cancer (mCRC): Translational analyses from the phase III BEBYP trial. 123
The role of primary tumour sidedness, EGFR gene copy number and EGFR promoter methylation in RAS/BRAF wild-type colorectal cancer patients receiving irinotecan/cetuximab 122
Autophagy-related polymorphisms predict hypertension in patients with metastatic colorectal cancer treated with FOLFIRI and bevacizumab: Results from TRIBE and FIRE-3 trials 121
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer 120
Case-report: folfoxiri plus bevacizumab in "poor-risk" liver-only metastatic colorectal cancer: case report and state-of-the-art. 119
Association of BRAF mutations and EGFR Intron-1 L/L genotype with resistance to cetuximab plus irinotecan treatment in KRAS wild-type metastatic colorectal cancer patients 118
Serum LDH predicts benefit from bevacizumab beyond progression in metastatic colorectal cancer 115
BRAF V600E mutation and amphiregulin (AR) immunohistochemical expression in the prediction of benefit from cetuximab plus irinotecan in KRAS wild-type metastatic colorectal cancer (MCRC) patients 114
Histopathologic evaluation of liver metastases from colorectal cancer in patients treated with FOLFOXIRI plus bevacizumab. 114
Prevention and management of adverse events related to regorafenib 114
DPYD and UGT1A1 genotyping to predict adverse events during first-line FOLFIRI or FOLFOXIRI plus bevacizumab in metastatic colorectal cancer 113
Chemotherapeutic and antiangiogenic drugs beyond tumor progression in colon cancer: evaluation of the effects of switched schedules and related pharmacodynamics 113
Cytotoxic triplets plus a biologic: state-of-the-art in maximizing the potential of up-front medical treatment of metastatic colorectal cancer 111
null 111
Genes involved in pericyte-driven tumor maturation predict treatment benefit of first-line FOLFIRI plus bevacizumab in patients with metastatic colorectal cancer 111
Differential histopathologic parameters in colorectal cancer liver metastases resected after triplets plus bevacizumab or cetuximab: a pooled analysis of five prospective trials 111
VEGF gene polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab (BV) in metastatic colorectal cancer (mCRC) patients (pts) 110
VEGF gene polymorphisms in the prediction of benefit from first-line folfiri plus bevacizumab (BV) in metastatic colorectal cancer (MCRC) patients (pts) 110
TRIPLETE: A randomised phase III study of modified FOLFOXIRI plus panitumumab versus mFOLFOX6 plus panitumumab as initial therapy for patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer 110
KRAS and BRAF mutational analyses in a phase II trial of first-line folfoxiri plus bevacizumab (BV) in metastatic colorectal cancer (MCRC) patients (pts) 107
Targeting vascular endothelial growth factor pathway in first-line treatment of metastatic colorectal cancer: state-of-the-art and future perspectives in clinical and molecular selection of patients 107
FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest (GONO). 107
Variations in genes regulating tumor-associated macrophages (TAMs) to predict outcomes of bevacizumab-based treatment in patients with metastatic colorectal cancer: Results from TRIBE and FIRE3 trials 107
FOLFOXIRI plus bevacizumab (bev) versus FOLFIRI plus beva s first-line treatment of metastatic colorectal cancer (MCRC): Results of the phase III randomized TRIBE trial. 106
BRAF-mutated metastatic colorectal cancer between past and future 106
Folfoxiri plus bevacizumab as first-line treatment in braf mutant metastatic colorectal cancer. 106
EZH2 polymorphism and benefit from bevacizumab in colorectal cancer: another piece to the puzzle 105
DPYD*6 plays an important role in fluoropyrimidine toxicity in addition to DPYD*2A and c.2846A>T: a comprehensive analysis in 1254 patients 105
KRAS and BRAF genotyping of synchronous colorectal carcinomas. 104
First-line therapy for mCRC-the influence of primary tumour location on the therapeutic algorithm 104
Location of primary tumor and benefit from anti-epidermal growth factorreceptor monoclonalantibodies in patients with RAS and BRAF wild-typemetastatic colorectal cancer 104
BRAF V600E mutation and Amphiregulin (AR) immunohistochemical expression in the prediction of benefit from cetuximab plus irinotecan in KRAS wild-type metastatic colorectal cancer (mCRC) patients 102
Histopathologic response to FOLFOXIRI plus bevacizumab of liver metastases from colorectal cancer. 102
High concordance of BRAF status between primary colorectal tumours and related metastatic sites: implications for clinical practice 102
Analysis of NRAS mutation as poor prognostic indicator and predictor of resistance to anti-EGFR monoclonal antibodies (anti-EGFRs) in metastatic colorectal cancer (mCRC) patients (pts). 101
ALK, ROS1, and NTRK rearrangements in metastatic colorectal cancer 101
Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: Final results of the randomized BEBYP trial 101
Estimating 12-weeks death probability in patients with refractory metastatic colorectal cancer: the Colon Life nomogram 100
Clinical and molecular determinants of extrahepatic disease progression in patients with metastatic colorectal cancer with liver-limited metastases deemed initially unresectable 100
KSR1 gene polymorphism in mCRC patients treated with first-line FOLFIRI and bevacizumab. 99
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer 99
The PANDA study: a randomized phase II study of first-line FOLFOX plus panitumumab versus 5FU plus panitumumab in RAS and BRAF wild-type elderly metastatic colorectal cancer patients 99
Amphiregulin (AR) expression in the prediction of benefit from cetuximab plus irinotecan in K-RAS wild-type metastatic colorectal cancer (mCRC) patients 98
Second-line chemotherapy (CT) with or without bevacizumab (BV) in metastatic colorectal cancer (mCRC) patients (pts) who progressed to a first-line treatment containing BV: Updated results of the phase III “BEBYP”trial by the Gruppo Oncologico Nord Ovest (GONO). 98
null 98
Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial 98
Do we need biopsies of metastases for colorectal cancer patients? 97
High activity and resection rate in molecularly selected patients with unresectable metastatic colorectal cancer (MCRC) treated with panitumumab (P) and folfoxiri as first-line therapy : a phase II study. 97
Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest 97
Folfoxiri in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest (GONO). 95
Prognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients 95
Glycolysis gene expression analysis and selective metabolic advantage in the clinical progression of colorectal cancer 95
Circulating tumor DNA analysis in colorectal cancer: From dream to reality 95
Risk for developing brain metastases from colorectal cancer in long-term survivors with lung metastases and KRAS mutations. 94
Variant alleles in factor V, prothrombin, plasminogen activator inhibitor-1, methylenetetrahydrofolate reductase and risk of thromboembolism in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab 94
ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer 94
Benefit from anti-EGFRs in RAS and BRAF wild-type metastatic transverse colon cancer: A clinical and molecular proof of concept study 93
Histopathological response to folfoxiri plus bevacizumab of liver metastases from colorectal cancer. 92
Clinical impact of anti-epidermal growth factor receptor monoclonal antibodies in first-line treatment of metastatic colorectal cancer: Meta-analytical estimation and implications for therapeutic strategies. 92
PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer 92
Polymorphisms in genes involved in EGFR turnover are predictive for cetuximab efficacy in colorectal cancer 92
Genetic variants of kinases suppressors of ras in KRAS-BREF wild-type metastatic colorectal cancer patients treated with cetuximab and irinotecan. 92
Host genetic variants in the Insulin Growth Factor Binding Protein-3 impact on servival of patients with advanced gastric cancer treated with palliative chemotharapy 91
null 91
Prevention of capecitabine toxicity using a 5-FU test dose 91
A multicenter, randomized phase III study of second-line chemotherapy (CT) with or without bevacizumab (BV) in metastatic colorectal cancer (MCRC) patients who progressed to a first-line treatment containing bv: results from the bebyp trial by the Gruppo Oncologico Nord Ovest (GONO). 91
Lack of Benefit From Anti-EGFR Treatment in RAS and BRAF Wild-type Metastatic Colorectal Cancer With Mucinous Histology or Mucinous Component 91
Early modifications of circulating microRNAs levels in metastatic colorectal cancer patients treated with regorafenib 91
AMPK variant, a candidate of novel predictor for chemotherapy in metastatic colorectal cancer: A meta-analysis using TRIBE, MAVERICC and FIRE3 91
null 90
Prognostic significance of KRAS mutation rate in metastatic colorectal cancer patients. 90
A new nomogram for estimating survival in patients with brain metastases secondary to colorectal cancer 90
Preliminary results from a phase II study of panitumumab (P) in combination with folfoxiri as first-line treatment of molecularly selected metastatic colorectal cancer (MCRC) patients (PTS) 90
Clinical impact of first-line bevacizumab plus chemotherapy in metastatic colorectal cancer of mucinous histology: a multicenter, retrospective analysis on 685 patients 90
Activity and Safety of Cetuximab Plus Modified FOLFOXIRI Followed by Maintenance With Cetuximab or Bevacizumab for RAS and BRAF Wild-type Metastatic Colorectal Cancer: A Randomized Phase 2 Clinical Trial. 90
Oral multikinase inhibitor regorafenib for the treatment of patients with metastatic colorectal cancer 89
Prospective analysis of the early modulation of plasma amphiregulin (AR) during treatment with cetuximab and irinotecan in irinotecan-refractory metastatic colorectal cancer (mCRC) patients (pts). 88
Biomarkers and response to bevacizumab--letter 88
Pharmacological effects of the simultaneous and sequential combinations of trifluridine/tipiracil (TAS-102) and 5-fluorouracil in fluoropyrimidine-sensitive colon cancer cells 88
Radiological imaging markers predicting clinical outcome in patients with metastatic colorectal carcinoma treated with regorafenib: post hoc analysis of the CORRECT phase III trial (RadioCORRECT study) 87
Primary side of origin affects the outcome of mCRC patients treated with first-line FOLFIRI plus bevacizumab independently of BRAF status and mucinous histology. 87
Predictors of benefit in colorectal cancer treated with cetuximab: are we getting "Lost in TranslationAL?" 87
Pharmacokinetic analysis of metronomic capecitabine in refractory metastatic colorectal cancer patients 86
Totale 10.646
Salva come PNG Salva come JPEG
Categoria #
all - tutte 78.730
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 78.730
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20202.786 0 0 0 0 400 475 457 351 422 285 291 105
2020/20212.136 150 143 74 79 118 321 109 143 286 138 133 442
2021/20222.601 36 91 40 73 464 478 52 82 184 172 162 767
2022/20233.384 450 433 219 330 336 418 43 210 597 34 281 33
2023/20243.584 291 330 509 233 474 516 264 97 177 134 202 357
2024/20251.266 167 400 171 461 67 0 0 0 0 0 0 0
Totale 22.836